Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...

Novo Nordisk also will provide free insulin to the neediest Minnesotans ... Insulin is vital to control blood sugar in patients with type 1 diabetes, and is used by some patients with the more ...